274 related articles for article (PubMed ID: 23850197)
1. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders.
Agustoni F; Platania M; Vitali M; Zilembo N; Haspinger E; Sinno V; Gallucci R; de Braud F; Garassino MC
Cancer Treat Rev; 2014 Feb; 40(1):197-203. PubMed ID: 23850197
[TBL] [Abstract][Full Text] [Related]
2. Ocular toxicity of targeted therapies.
Renouf DJ; Velazquez-Martin JP; Simpson R; Siu LL; Bedard PL
J Clin Oncol; 2012 Sep; 30(26):3277-86. PubMed ID: 22649132
[TBL] [Abstract][Full Text] [Related]
3. Update on ocular complications of systemic cancer chemotherapy.
Schmid KE; Kornek GV; Scheithauer W; Binder S
Surv Ophthalmol; 2006; 51(1):19-40. PubMed ID: 16414359
[TBL] [Abstract][Full Text] [Related]
4. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
[TBL] [Abstract][Full Text] [Related]
5. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
6. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden.
Stepanski EJ; Houts AC; Schwartzberg LS; Walker MS; Reyes CM; Blakely J
Clin Lung Cancer; 2009 Nov; 10(6):426-32. PubMed ID: 19900861
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
8. Ocular toxicity and cancer chemotherapy. A review.
al-Tweigeri T; Nabholtz JM; Mackey JR
Cancer; 1996 Oct; 78(7):1359-73. PubMed ID: 8839540
[TBL] [Abstract][Full Text] [Related]
9. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Conclusion.
Bunn PA; Thatcher N
Oncologist; 2008; 13 Suppl 1():37-46. PubMed ID: 18263773
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
11. [The quality of life after chemotherapy in advanced non-small cell lung cancer patients].
Słowik-Gabryelska A; Szczepanik A; Kalicka A
Pol Merkur Lekarski; 1999 Jan; 6(31):18-22. PubMed ID: 10344148
[TBL] [Abstract][Full Text] [Related]
12. Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer.
Nguewa PA; Calvo A; Pullamsetti SS; Banat GA; Grimminger F; Savai R
Expert Opin Investig Drugs; 2011 Jan; 20(1):61-74. PubMed ID: 21142806
[TBL] [Abstract][Full Text] [Related]
13. Update on the role of topotecan in the treatment of non-small cell lung cancer.
Stewart DJ
Oncologist; 2004; 9 Suppl 6():43-52. PubMed ID: 15616149
[TBL] [Abstract][Full Text] [Related]
14. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.
Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G
J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
17. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
18. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China.
Yu YF; Chen ZW; Zhou Z; Song ZB; Li ZM; Jian H; Zhang YF; Lu S
Chemotherapy; 2010; 56(6):472-7. PubMed ID: 21099219
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight.
Min JH; Lee HY; Lim H; Ahn MJ; Park K; Chung MP; Lee KS
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1099-109. PubMed ID: 21913033
[TBL] [Abstract][Full Text] [Related]
20. [New cytotoxics in the treatment of bronchial cancers].
Quantin X; Godard P; Michel FB; Pujol JL
Rev Mal Respir; 1998 Oct; 15(5):597-612. PubMed ID: 9834987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
